United Therapeutics Patent Lawsuit Update

United Therapeutics, a biotechnology company, is involved in a patent lawsuit against Liquidia, as reported by grafa.com on May 12, 2025.

Lawsuit Details

The lawsuit is ongoing, with no further information available at this time.

Stock Performance

United Therapeutics’ stock price has fluctuated over the past year, with a 52-week high of $417.82 on November 7, 2024. The stock’s 52-week low was $264.33 on May 28, 2024.

Current Valuation

As of the last close, United Therapeutics traded at $305.35 per share, with a price-to-earnings ratio of 12.12 and a price-to-book ratio of 2.01.

Key Financial Metrics

• Price-to-earnings ratio: 12.12
• Price-to-book ratio: 2.01